Business, energy, technology, markets and global industry news from Business News Today

autosomal dominant polycystic kidney disease

PharmaDeviceNews autosomal dominant polycystic kidney disease
Arcus Biosciences casdatifan data test whether next-generation HIF-2α inhibition can outperform late-line kidney cancer expectations
Pharma & Biotech

Estuary launches with $103m to develop gene therapies for polycystic kidney disease

Estuary Biotherapeutics has launched with $103 million in committed financing to develop kidney-targeted gene therapies for autosomal dominant polycystic kidney disease. Its two lead programmes target PKD2 and PKD1 mutations, building on mouse research suggesting that restoring polycystin activity can reverse some features of established kidney disease.

Read More
Mezzion’s investigational drug udenafil has reduced kidney cyst burden in an ADPKD animal study, strengthening the scientific rationale for the company’s planned Phase 2b clinical programme. Representative image.
Pharma & Biotech

Mezzion’s new kidney disease data sent shares higher, but the decisive test is still ahead

Mezzion reports animal-model ADPKD data for udenafil as it prepares Phase 2b testing. The findings support development, but human efficacy is unproven.

Read More
Pharma & Biotech

How XORTX is linking gout to genetics and reshaping the future of precision uric acid therapies

XORTX is using new genetic research to strengthen its case for oxypurinol in gout and kidney disease. Find out how this could shape the future of precision nephrology.

Read More